ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 145 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $892,888 | -44.2% | 86,103 | -56.5% | 0.41% | -68.6% |
| Q1 2023 | $1,600,226 | -45.8% | 197,803 | +5.4% | 1.30% | -25.7% |
| Q4 2022 | $2,954,999 | -13.8% | 187,619 | -13.9% | 1.75% | -10.4% |
| Q3 2022 | $3,428,000 | +12.9% | 217,818 | +0.1% | 1.96% | +6.8% |
| Q2 2022 | $3,037,000 | +11.3% | 217,528 | +37.5% | 1.83% | +5.7% |
| Q1 2022 | $2,728,000 | +67.3% | 158,243 | +41.1% | 1.73% | +33.6% |
| Q4 2021 | $1,631,000 | -2.6% | 112,160 | +20.6% | 1.30% | +17.1% |
| Q3 2021 | $1,675,000 | +140.3% | 93,000 | +134.4% | 1.11% | +124.3% |
| Q2 2021 | $697,000 | – | 39,675 | – | 0.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |